Drug
Nirogacestat
Nirogacestat: highest development phase Post-Market, developed by Merck. 6 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nirogacestat NCT07176689 | Post-Market | Desmoid Tumor |
| Nirogacestat oral tablet NCT03785964 | Phase 3 | Desmoid Tumor |
| Nirogacestat oral tablet NCT07170644 | Phase 2 | Desmoid Tumor |
| Nirogacestat NCT05348356 | Phase 2 | Ovarian Granulosa-Stromal Tumor |
| Nirogacestat NCT07171619 | Phase 1 | Healthy |
| Nirogacestat NCT07259330 | Phase 1 | Healthy |
Latest
No recent events.
Follow Nirogacestat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.